Literature DB >> 32513810

Covid-19: Hydroxychloroquine does not benefit hospitalised patients, UK trial finds.

Ingrid Torjesen1.   

Abstract

Entities:  

Year:  2020        PMID： 32513810     DOI： 10.1136/bmj.m2263

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  17 in total

1.  Preparedness and activities of the anti-SARS-CoV-2 convalescent plasma bank in the Veneto region (Italy): An organizational model for future emergencies.

Authors:  Giustina De Silvestro; Giorgio Gandini; Francesco Fiorin; Piero Marson; Ersilia Barbone; Andrea Frigato; Gianluca Gessoni; Arianna Veronesi; Monia Pacenti; Monica Castelli; Marianna Rinaldi; Monica Rizzi; Francesca Stefani; Giovanni Roveroni
Journal:  Transfus Apher Sci       Date:  2021-05-07       Impact factor: 1.764

Review 2.  Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection.

Authors:  Chang Li; Lin Wang; Linzhu Ren
Journal:  Virus Res       Date:  2020-06-24       Impact factor: 3.303

Review 3.  Might proton pump or sodium-hydrogen exchanger inhibitors be of value to ameliorate SARs-CoV-2 pathophysiology?

Authors:  Kirk P Conrad
Journal:  Physiol Rep       Date:  2021-01

Review 4.  Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications.

Authors:  Ioannis P Trougakos; Kimon Stamatelopoulos; Evangelos Terpos; Ourania E Tsitsilonis; Evmorfia Aivalioti; Dimitrios Paraskevis; Efstathios Kastritis; George N Pavlakis; Meletios A Dimopoulos
Journal:  J Biomed Sci       Date:  2021-01-12       Impact factor: 8.410

5.  Quality Assessment of the Chinese Clinical Trial Protocols Regarding Treatments for Coronavirus Disease 2019.

Authors:  Jiaxing Zhang; Yiling Lu; Joey Sum-Wing Kwong; Xiaosi Li; Wenyi Zheng; Rui He
Journal:  Front Pharmacol       Date:  2020-08-27       Impact factor: 5.810

6.  Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis.

Authors:  Yanxiang Zang; Xuejie Han; Meijiao He; Jing Shi; Yue Li
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-09-06       Impact factor: 3.000

7.  Signal amplification by reversible exchange for COVID-19 antiviral drug candidates.

Authors:  Hye Jin Jeong; Sein Min; Heelim Chae; Sarah Kim; Gunwoo Lee; Sung Keon Namgoong; Keunhong Jeong
Journal:  Sci Rep       Date:  2020-08-31       Impact factor: 4.379

8.  SARS-CoV-2 Infection and COVID-19 in 5 Patients in Ecuador After Prior Treatment with Hydroxychloroquine for Systemic Lupus Erythematosus.

Authors:  María Fernanda Zurita; Adriana Iglesias Arreaga; Adriana A Luzuriaga Chavez; Luis Zurita
Journal:  Am J Case Rep       Date:  2020-09-26

9.  No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19.

Authors:  Klinger Soares Faíco-Filho; Danielle Dias Conte; Luciano Kleber de Souza Luna; Joseane Mayara Almeida Carvalho; Ana Helena Sitta Perosa; Nancy Bellei
Journal:  Braz J Microbiol       Date:  2020-10-27       Impact factor: 2.476

10.  Hydroxychloroquine for treatment of nonsevere COVID-19 patients: Systematic review and meta-analysis of controlled clinical trials.

Authors:  Hozaifa Khalil Elsawah; Mohamed Ahmed Elsokary; Mahmoud Gamal Elrazzaz; Ahmed Hanei Elshafie
Journal:  J Med Virol       Date:  2020-09-29       Impact factor: 20.693
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.